Genmab As Stock Market Capitalization
GMAB Stock | DKK 2,007 51.00 2.48% |
Genmab AS fundamentals help investors to digest information that contributes to Genmab AS's financial success or failures. It also enables traders to predict the movement of Genmab Stock. The fundamental analysis module provides a way to measure Genmab AS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genmab AS stock.
Genmab |
Genmab AS Company Market Capitalization Analysis
Genmab AS's Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Genmab AS Market Capitalization | 185.21 B |
Most of Genmab AS's fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genmab AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
Competition |
Based on the recorded statements, the market capitalization of Genmab AS is about 185.21 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The market capitalization for all Denmark stocks is significantly lower than that of the firm.
Genmab Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genmab AS's direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics of similar companies.Genmab AS is currently under evaluation in market capitalization category among related companies.
Genmab Fundamentals
Return On Equity | 0.24 | |||
Return On Asset | 0.1 | |||
Profit Margin | 0.47 % | |||
Operating Margin | 0.38 % | |||
Current Valuation | 186.33 B | |||
Shares Outstanding | 65.96 M | |||
Shares Owned By Institutions | 49.90 % | |||
Price To Earning | 34.78 X | |||
Price To Book | 7.86 X | |||
Price To Sales | 17.00 X | |||
Revenue | 8.48 B | |||
Gross Profit | 8.48 B | |||
EBITDA | 4.24 B | |||
Net Income | 3.01 B | |||
Cash And Equivalents | 18.08 B | |||
Cash Per Share | 276.57 X | |||
Total Debt | 378 M | |||
Debt To Equity | 0.02 % | |||
Current Ratio | 15.42 X | |||
Book Value Per Share | 408.67 X | |||
Cash Flow From Operations | 2.23 B | |||
Earnings Per Share | 83.21 X | |||
Price To Earnings To Growth | 1.19 X | |||
Target Price | 3239.73 | |||
Number Of Employees | 1.56 K | |||
Beta | 0.67 | |||
Market Capitalization | 185.21 B | |||
Total Asset | 24.63 B | |||
Net Asset | 24.63 B |
About Genmab AS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Stocks Directory Find actively traded stocks across global markets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |